期刊文献+

荷瘤小鼠肿瘤细胞凋亡显像的实验研究 被引量:2

Experimental study on tumor cell apoptosis imaging in vivo with ^(99)Tc^m-HYNIC-Annexin Ⅴ in mice tumor-bearing
下载PDF
导出
摘要 目的研究细胞凋亡显像剂99Tcm-HYNIC-AnnexinⅤ的制备及其在荷瘤小鼠体内的生物分布特性和活体显像。方法采用双功能螯合剂HYNIC法锝[99Tcm]标记AnnexinⅤ,经高效液相色谱仪分离纯化并检测标记产物。建立荷肿瘤小鼠模型,在20~25 g昆明种小白鼠右前腋下皮下接种S-180肉瘤,生长1周。荷瘤小鼠在环磷酰胺腹腔内给药化疗72 h后,尾静脉注射99Tcm-HYNIC-AnnexinⅤ,分别于5 min3、0 min、1 h、3 h、6 h后进行SPECT显像和体内生物分布测定。实验结果应用SPSS 12.0统计学软件进行统计学分析。结果99Tcm-HYNIC-AnnexinⅤ的标记率达到95%,放射性化学纯度为99%。荷瘤小鼠在环磷酰胺腹腔内给药化疗后72 h显像可见:注射99Tcm-HYNIC-AnnexinⅤ后6 h肿瘤组织呈明显异常放射性浓聚灶。体内生物分布实验观察到,注射显像剂后6 h肿瘤组织的放射性摄取值(1.59±0.44)最高,与其他时相的肿瘤组织放射性摄取值比较P<0.05。99Tcm-HYNIC-AnnexinⅤ主要聚集在肾脏、肺脏和肝脏等,从肾脏排泄,其血流清除速度快,在注射后30 min,血液放射性摄取值(1.59±0.50)仅为5 min时(8.85±2.65)的20%(P<0.05)。注射显像剂后6 h,肿瘤/肌肉放射性摄取率比值(3.73±1.42)高于肿瘤/血液放射性摄取率比值(2.80±0.54)。结论99Tcm-HYNIC-Annexin V有望成为一种富有应用前景的活体细胞凋亡分子探针。 Objective To investigate in vivo the imaging and hoidistrihution characters of 99^Tc^m-HYNIC-Annexin V as tumor cell apoptosis imaging agent in tumor hearing mice. Methods Annexin V was laheled with technetium-99m using a hydrazino-nicotinamide (HYNIC) method, then isolated and identified with high performance liquid chromatography (HPLC). One week after heing inoculated with S-180 sarcoma in the right upper limhs, the mice were randomized to receive a single dose of cyclophosphamide (150 mg/kg intraperitoneally), and were injected through tail vein with 99 ^Tc^m HYNIC- Annexin V 72 hours later. The images and radioactivity in tissues were ohtained at 5 min, 30 min, 1 h, 3 h and 6 h postinjenction of imaging agent, respectively. The data of radioactivity in tissues were analyzed hy the statistic software of SPSS 12.0. Results The laheling efficiency and radiochemical purity of HYNIC-Annexin V laheled with technetium-99m reached 95% and 99%, respectively. Abnormal and marked uptake of radioactivity in tumor tissue in tumor-bearing mice received cyclophosphamide intraperitoneally was found to he at 6 h postinjection. Compared with that in tumor tissue at different time point of postinjection, the ratio (1.59 ± 0.44)% ID/g in tumor tissue at 6 h after injection of imaging agent showed the most important (P〈0.05). The 99^Tc^m HYNIC Annexin V accumulated mainly in the kidney, lung and liver. It was cleared quickly through blood. In comparison with activity ([8.85±1. 65]%ID/g) at 5 min postinjection, 20 percents of initial activity remained in blood ([1.59±0.50]%ID/g) at 30 min. The ratio ([3.73±1.42]%ID/g) of tumor/muscle was higher than that of tumor/blood ([2.80±0. 54]%ID/g). Conclusion 99^Tc^m- HYNIC Annexin V appears to be a potential and useful molecular probe of tumor cell apoptosis.
出处 《中国医学影像技术》 CSCD 北大核心 2005年第11期1663-1666,共4页 Chinese Journal of Medical Imaging Technology
基金 国家自然科学基金资助项目(10275003)
关键词 细胞凋亡 99Tcm-HYNIC-Annexin 放射性核素显像 荷瘤小鼠 生物分布 Apoptosis 99^Tc^m -HYNIC-Annexin V Radionuclide imaging Bearing-tumor mice Biodistribution
  • 相关文献

参考文献15

  • 1王荣福.肿瘤影像核医学进展[J].中国医学影像技术,2004,20(11):1792-1796. 被引量:16
  • 2Thompson BC. Apoptosis in the pathogenesis and treatment of disease[J]. Science,1995,267(5203):1456-1462.
  • 3王荣福,刘萌.放射性AnnexinⅤ活体细胞凋亡显像在肿瘤研究中的应用及进展[J].中国医学影像技术,2004,20(10):1616-1619. 被引量:11
  • 4Blankenberg FG, Tait JF, Strauss HW. Apoptotic cell death: its implications for imaging in the next millennium[J]. Eur J Nucl Med,2000,27(3):359-367.
  • 5Kemerink GJ, Liu K, Kieffer D, et al. Safty, biodistribution, and dosimetry of 99Tcm- HYNIC-Annexin Ⅴ, a novel human recombinant annexin V for human application[J]. J Nucl Med,2003,44(6):947-952.
  • 6陈大明.放射性Annexin V的细胞凋亡显像剂研究[C].北京:中国原子能科学研究院,2004..
  • 7罗全勇,朱瑞森.活体内探测细胞凋亡的影像学技术[J].中国医学影像技术,2004,20(10):1620-1623. 被引量:4
  • 8van Heerde WL, de Groot PG, Reutelingsperger CP. The complexity of the phospholipid binding protein Annexin Ⅴ[J]. Thromb Haemost,1995,73(2):172-179.
  • 9Tait JF. Clinical application of Annexins. In: Seton BA. Annexins:molecular structure to cellular function[M]. NewYork: RG, Landes,1996,213-220.
  • 10Pigault C, Follenius-Wund A, Chabbert M. Role of Trp-187 in the Annexin Ⅴ-membrane interaction: a molecular mechanics analysis[J]. Biochem Biophys Res Commun,1999,254(2):484-489.

二级参考文献67

  • 1王荣福,张春丽.Clinical application of radioimmunoi maging with (99)~m Tc-BDI-1in the diagnosis of bladder cancer[J].Chinese Medical Journal,2000(5):12-15. 被引量:5
  • 2[1]Thompson BC. Apoptosis in the pathogenesis and treatment of disease[J]. Science, 1995, 267(5203): 1456-1462.
  • 3[2]Saikumar P, Dong Z, Mikhailov V, et al. Apoptosis: definition, mechanisms, and relevance to disease[J]. Am J Med, 1999,107(5):489-506.
  • 4[3]Denecker G, Dooms H, Van Loo G, et al. Phosphatidylserine exposure during apoptosis precedes release of cytohromec and decrease in mitochondrial transmembrane potential[J]. FEBS Lett, 2000,465(1):47-52.
  • 5[4]Lahorte C, Slegers G, Philippé J, et al. Synthesis and in vitro evaluation of 123I-labelled human recombinant annexin V[J]. Biomol Eng, 2001,17(2):51-53.
  • 6[5]Lahorte C, van de Wiele C, Bacher K, et al. Biodistribution and dosimetry study of 123I-rh-Annexin V in mice and humans[J]. Nucl Med Commun, 2003,24(8):871-880.
  • 7[6]Russell J, O' Donoghue JA, Finn R, et al. Iodination of Annexin V for imaging apoptosis[J]. J Nucl Med, 2002, 43(5):671-677.
  • 8[7]Kown MH, Strauss HW, Blankenberg FG, et al. In vivo imaging of acute cardiac allograft rejection in human patients using 99m-technetium labeled annexin V[J]. Am J Transplant, 2001,1(3):270-277.
  • 9[8]Blankenberg FG, Katsikis PD, Tait JF, et al. In vivo detection and imaging of phosphatidylserine expression during programmed cell death[J]. Proc Natl Acad Sci USA, 1998, 95(11):6349-6354.
  • 10[9]Kemerink GJ, Liem IH, Hofstra L, et al. Patient dosimetry of intravenously administered 99Tcm-Annexin[J]. J Nucl Med, 2001,42(2):382-387.

共引文献33

同被引文献19

  • 1罗全勇,朱瑞森.活体内探测细胞凋亡的影像学技术[J].中国医学影像技术,2004,20(10):1620-1623. 被引量:4
  • 2兰晓莉,张永学,安锐,高再荣,曹国祥.~99TC^m-HYNIC-Annexin V的制备及其在健康小鼠体内的分布[J].中华核医学杂志,2005,25(6):344-346. 被引量:9
  • 3韦华,郝晓柯,苏明权.多肽K237与前列腺癌细胞系LNcap的亲和性[J].现代肿瘤医学,2007,15(1):10-12. 被引量:5
  • 4Boersma HH, Kietselaer BLJH, Stolk MML, et al. Past, present, and future of annexin A5: from protein discovery to clinical applications. J Nucl Med, 2005,46(12) : 2035-2050.
  • 5Tang XN, Wang Q, Koike MA, et al. Monitoring the protective effects of minoeycline treatment with radiolabeled annexin V in an experimental model of focal cerebral ischemia. J Nucl Med, 2007, 48(11) :1822-1828.
  • 6Kartachova MS, Valdes Olmos RA, Haas RL, et al. ^99mTc-HYN IC-rh-annexin-V scintigraphy: visual and quantitative evaluation of early treatment-induced apoptosis to predict treatment outcome. Nucl Med Commun, 2008,29(1) :39-44.
  • 7Tait JF, Smith C, Blankenberg FG. Structural requirements for in vivo detection of cell death with ^99mTc-annexin V. J Nucl Med, 2005,46(5) :807-815.
  • 8Lan XL, Zhang YX. Preparation of ^99mTc-HYNIC-Annexin V. Nuclear Science and Techniques, 2005,16 (5) : 299-303.
  • 9Hersey P, Zhang XD, Mhaidat N. Overcoming resistance to apoptosis in cancer therapy. Adv Exp Med Biol, 2008,615:105-126.
  • 10Camins A, Pallas M, Silvestre JS. Apoptotic mechanisms involved in neurodegenerative diseases: experimental and therapeutic approaches. Methods Find Exp Clin Pharmacol, 2008,30 ( 1 ) :43-65.

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部